Repercussão cardiovascular das terapias anticâncer / Cardiovascular outcomes of anticancer therapies

Júlia Oliveira Silva, Marcelo de Araújo Lopes Júnior, Ingridy Maria Oliveira Ferreira, Beatriz Vieira Nascimento Silva

Abstract


A quimioterapia constitui-se como uma das principais linhas de tratamento do câncer na atualidade. Entretanto, dentre todas as reações adversas relacionadas a estes métodos terapêuticos, as cardiovasculares têm-se evidenciado como um fator importante e incapacitante. Com o objetivo de conhecer e apresentar de forma prática as drogas oncológicas com maior potencial cardiotóxico, foi realizada uma revisão de literatura embasada nas plataformas Pubmed, LILACS e SciElo no intervalo de 2007 a 2019. Os resultados da revisão mostraram uma série de efeitos cardiovasculares que podem ser provocados devido ao uso de tratamento com medicamentos anticâncer. Dessa forma, o acompanhamento dos pacientes e o monitoramento, por meio de histórico médico e exames cardiológicos, evidenciam-se como formas de prevenção e podem proporcionar uma melhora na qualidade de vida e no prognóstico das neoplasias malignas.


Keywords


Cardiotoxicidade; Imunoterapia; Cardiopatias e Quimioterapia.

References


Campbell P, Stuart J, Getz G, Krobel J, Stein L. Pan-cancer analysis of whole genomes. Nature [Internet]. 2020 Feb 05 [cited 2021 May 25]; 578:82–93. DOI https://doi.org/10.1038/s41586-020-1969-6.

Rang HP, Ritter JM, Flower RJ, Handerson G. Rang & Dale Farmacologia. 8th ed.: Elsevier Brasil; 2016. ISBN: 9788535283433.

Varricchi G, Galfiero MR, Marone G, Criscuolo G, Triassi Maria, Bonaduce D, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open [Internet]. 2017 [cited 2021 May 25]; 2(4) DOI https://doi.org/10.1136/esmoopen-2017-000247.

Diretriz Brasileira de Cardio-oncologia – 2020. Arquivos Brasileiros de Cardiologia [Internet]. 2020 [cited 2021 May 25]; 115(5):1006-1043. DOI https://doi.org/10.36660/abc.20201006.

Albini A, Pennesi G, Donatell Fi, Cammarota R, Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute [Internet]. 2010 [cited 2021 May 25]; 102(1): 14-25. DOI https://doi.org/10.1093/jnci/djp440.

Lenneman CG, Sawyer DB. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circulation Research [Internet]. 2016 [cited 2021 May 25]; 118(6): 1008-1020. DOI https://doi.org/10.1161/CIRCRESAHA.115.303633.

Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of Immune Therapy. Cardiology Clinics [Internet]. 2019 [cited 2021 May 25]; 37(4): 385-397. DOI https://10.1016/j.ccl.2019.07.008.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journals of the American College of Cardiology [Internet]. 2018 [cited 2021 May 25];71(16):1755-1764. DOI 10.1016/j.jacc.2018.02.037.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. The New England Journal of Medicine [Internet]. 2016 [cited 2021 May 25];375(18):1749-1755. DOI 10.1056/NEJMoa1609214.

Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry [Internet]. 2018 [cited 2021 May 25];25(11):1327-1339. DOI 10.2174/0929867324666170407125017.

Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology Heart and Circulatory Physiology [Internet]. 2015 [cited 2021 May 25];309(9):H1453-67. DOI 10.1152/ajpheart.00554.2015.

Asnani A. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. Current Oncology Reports [Internet]. 2018 [cited 2021 May 25];20(6):44. DOI 10.1007/s11912-018-0690-1.

Adão R, Keulenaer G, Leite-Moreira A, Brás-Silva C. Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. Revista Portuguesa de Cardiologia [Internet]. 2013 [cited 2021 May 25];32(5):395-409. DOI 10.1016/j.repc.2012.11.002.

Whalen K, Finkel R, Panavelil TA. Farmacologia ilustrada. 6th ed.: Artmed Editora; 2016. ISBN: 978-85-8271-323-5.

Pinto CM, Silva DC, Pinto GH, Santos MHH . Quimioterapia e Cardiotoxicidade. Revista da Sociedade de Cardiologia do Estado de São Paulo [Internet]. 2017 [cited 2021 May 25];27(4):266-273. DOI http://dx.doi.org/10.29381/0103-8559/20172704266-73.

Martel S, Maurer C, Lambertini M, Pondé N, Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opinion on Drug Safety [Internet]. 2017 [cited 2021 May 25];16(9):1021-1038. DOI 10.1080/14740338.2017.1351541.

Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. The Breast Journal [Internet]. 2014 [cited 2021 May 25];23(4):317-328. DOI 10.1016/j.breast.2014.04.002.

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2). U. S. National Library of Medicine [Internet]. 2017 [cited 2021 May 25]; Identifier: NCT00863655.

Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews [Internet]. 2014 [cited 2021 May 25];40(1):190-196. DOI 10.1016/j.ctrv.2013.04.005.

Nguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff P, et al. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. European Urology [Internet]. 2015 [cited 2021 May 25];67(5):825-836. DOI https://doi.org/10.1016/j.eururo.2014.07.010.

Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. Current Oncology Reports [Internet]. 2016 [cited 2021 May 25];18(6):35. DOI 10.1007/s11912-016-0521-1.

Zhang J, Chen W, Alvarez JB, Jia K, Shi L, Wang Q, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica volume [Internet]. 2018 [cited 2021 May 25];39:1693-1698. DOI https://doi.org/10.1038/s41401-018-0062-2.

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal of Imunotherapy of Cancer [Internet]. 2016 [cited 2021 May 25];40:50. DOI 10.1186/s40425-016-0152-y.

Grabie N, Lichtman A, Padera R. T cell checkpoint regulators in the heart. Cardiovascular Research [Internet]. 2019 [cited 2021 May 25];115(5):869-877. DOI 10.1093/cvr/cvz025.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine. 2015 [cited 2021 May 25];372(26):2521-2532. DOI 10.1056/NEJMoa1503093.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England Journal of Medicine [Internet]. 2015 [cited 2021 May 25];372(21):2006-2017. DOI 10.1056/NEJMoa1414428.

Truong J, Yan AT, Cramarossa G, Chan KKW. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Canadian Journal of Cardiology [Internet]. 2014 [cited 2021 May 25];30(8):869-878. DOI 10.1016/j.cjca.2014.04.029.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet Oncology [Internet]. 20105 [cited 2021 May 25];16(5):522-530. DOI 10.1016/S1470-2045(15)70122-1.

Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al. Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. Targeted Oncology. 2018 [cited 2021 May 25];13(4):509-515. DOI 10.1007/s11523-018-0579-9.

Rahouma M, Karim NA, Baudo M, Yahia M, Kamel M, Eldessouki I, et al. Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Immunotherapy [Internet]. 2019 [cited 2021 May 25];11(8):725-735. DOI 10.2217/imt-2018-0118.

Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular Toxicities Associated with Cancer Immunotherapies. Current Cardiology Reports [Internet]. 2017 [cited 2021 May 25];19(3):21. DOI 10.1007/s11886-017-0835-0.

Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology & Oncology [Internet]. 2019 [cited 2021 May 25];12(1):92. DOI 10.1186/s13045-019-0779-5.

Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. International Immunopharmacology [Internet]. 2019 [cited 2021 May 25];16:105866. DOI 10.1016/j.intimp.2019.105866.

Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Stavrakis MJ, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation AHA/ASA Journals [Internet]. 2007 [cited 2021 May 25];116(18):2062-2071. DOI 10.1161/CIRCULATIONAHA.107.709360.

Tarrio ML, Grabie N, Bu D, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. The Journal of Immunology [Internet]. 2012 [cited 2021 May 25];(188):4876-4884. DOI 10.4049/jimmunol.1200389.




DOI: https://doi.org/10.34119/bjhrv4n5-118

Refbacks

  • There are currently no refbacks.